Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare
JAMA Internal Medicine · 2026
DOI: 10.1001/jamainternmed.2026.2864 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, 2026. Verfasst von Aaron P Mitchell und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Medicare Part C, Medicare, Neoplasms, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Importance Use of Medicare Advantage (MA) insurance has been associated with lower cancer treatment costs than traditional Medicare (TM). Whether there are differences in guideline-concordant care or treatment costs for beneficiaries insured under MA vs TM is unknown.
Objective
To assess whether Medicare insurance type is associated with receipt of optimal cancer treatment and costs. Design, Setting, and Participants Retrospective cohort study of a population-based sample using Medicare claims and encounter data from 2015 through 2019. Participants were Medicare beneficiaries with continuous enrollment in either MA or TM and an incident cancer diagnosis from 2016 through 2019. Included patients were those with cancer treatment scenarios (eg, metastatic melanoma, adjuvant therapy for stage III colon cancer) that had substantial variation in the costs of recommended treatment options. Data were analyzed from April 2025 to March 2026. Exposures Medicare insurance type of MA or TM. Main Outcomes and Measures The pharmacologic cancer treatment among the available options each patient initiated was analyzed using Medicare data. Each patient’s treatment was linked by diagnosis date to contemporary National Comprehensive Cancer Network Guidelines recommendations and Medicare reimbursement rates to ascertain the coprimary outcomes whether a patient received the optimal treatment for their cancer type and the anticipated cost of the initiated treatment. The association of outcomes with insurance type was accessed using generalized estimating equations to estimate risk ratios (RRs) after balancing patient characteristics through inverse probability-of-treatment weighting. Models were clustered at the physician level and adjusted for scenario, diagnosis year, scenario × diagnosis year interaction, and oncologist characteristics.
Results
Of 35 245 patients (median age, 74 [IQR 70-79] years; 63.2% male), 24 269 had TM and 10 976 had MA. The median time to treatment initiation was 36 (IQR, 20-60) days for MA vs 35 (IQR, 19-59) days for TM. The unadjusted mean (SD) treatment cost was $29 252 ($80 391) for MA vs $40 874 ($106 205) for TM. MA beneficiaries had a likelihood of optimal treatment similar to TM beneficiaries (adjusted RR, 0.99; 95% CI, 0.97-1.02), and MA was associated with lower treatment cost (adjusted cost ratio, 0.94; 95% CI, 0.91- 0.97). Mean savings within this patient cohort was −$931 (95% CI, −$1244 to −$615). Conclusions and Relevance In this cohort study of Medicare beneficiaries with cancer, MA beneficiaries had lower estimated treatment costs and similar likelihood of receiving optimal treatment compared with TM beneficiaries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Health Policy and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Finance, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pharmacy Systems Outcomes and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago.
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, Pennsylvania.
Förderung
- NCI NIH HHS
- NIA NIH HHS
Zitieren
APA
Mitchell, A. P., Dusetzina, S. B., Mishra Meza, A., Gallagher, G., Augello, P., Fuchs, H., Guzman, G., Abdelaziz, A., Tabatabai, S., Persaud, S., Chakraborty, N., Blinder, V. S., Epstein, A. S., Daly, B., Wood, W. A., Winn, A. N., Gönen, M., & Jung, J. (2026). Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.2864
Vancouver
Mitchell AP, Dusetzina SB, Mishra Meza A, Gallagher G, Augello P, Fuchs H, et al. Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.2864
BibTeX
@article{Mitchell2026,
author = {Mitchell, Aaron P and Dusetzina, Stacie B and Mishra Meza, Akriti and Gallagher, Grace and Augello, Patrick and Fuchs, Hannah and Guzman, Gabrielle and Abdelaziz, Abdullah and Tabatabai, Sara and Persaud, Sonia and Chakraborty, Nirjhar and Blinder, Victoria S and Epstein, Andrew S and Daly, Bobby and Wood, William A and Winn, Aaron N and Gönen, Mithat and Jung, Jeah},
title = {Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare},
journal = {JAMA Internal Medicine},
year = {2026},
doi = {10.1001/jamainternmed.2026.2864}
}
EUVIMED